Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study.
This study evaluated safety and efficacy of esterified estrogens and methyltestosterone administered alone or in combination for the treatment of hot flashes in menopausal women. The 0.30-mg esterified estrogens and 0.30-mg methyltestosterone combination was the lowest effective dose, and our results are consistent with the known safety profile of estrogen and androgen combination products.
Liu
James
J
Case Medical Center, MacDonald Women's Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Allgood
Adam
A
Derogatis
Leonard R
LR
Swanson
Stephen
S
O'Mahony
Michael
M
Nedoss
Bertrand
B
Soper
Herbert
H
Zbella
Edward
E
Prokofieva
Svetlana Vladimirovna
SV
Zipfel
Lisa
L
Guo
Chun-Yuan
CY
D045930:Anabolic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects; D042724:Estrogens, Esterified (USP) / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D008593:Menopause / Q000187:drug effects; D008777:Methyltestosterone / Q000008:administration & dosage* / Q000009:adverse effects; D010919:Placebos; D012720:Severity of Illness Index; D016896:Treatment Outcome
D045930:Anabolic Agents; D004967:Estrogens; D042724:Estrogens, Esterified (USP); D010919:Placebos; D008777:Methyltestosterone